FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313471630> ?p ?o ?g. }

• W4313471630 endingPage "92" @default.
• W4313471630 startingPage "92" @default.
• W4313471630 abstract "Background and Objectives: Acetylsalicylic acid (ASA) is widely used for preventing cerebrovascular and cardiovascular diseases. Gastrointestinal (GI) tract injury is one of the major complications of aspirin use, potentially leading to severe GI bleeding. However, no drugs for preventing aspirin-induced small intestinal injury have been developed. The aim of this study was to establish a human experimental model for investigating aspirin-induced small intestinal mucosal injury. In addition, we evaluated the protective effect of Irsogladine against aspirin-induced small intestinal mucosal injury using human induced pluripotent stem cell-derived 2D monolayer crypt-villus structural small intestine (2D-hiPSC-SI). Materials and Methods: Human iPS cell-derived intestinal organoids were seeded and cultured in Air-liquid interface. The permeability of 2D-hiPSC-SI was evaluated using Lucifer yellow. Changes in structure and mucosal permeability of 2D-hiPSC-SI after addition of aspirin were confirmed over time, and changes in intestinal epithelium-related markers were evaluated by real-time qPCR and Immunofluorescence staining. The effect of Irsogladine on prevention of aspirin mucosal injury was examined by adding Irsogladine to the culture medium. Results: Cultured 2D-hiPSC-SI showed multi-lineage differentiation into small intestinal epithelium comprised of absorptive cells, goblet cells, enteroendocrine cells, and Paneth cells, which express CD10, MUC2, chromogranin A, and lysozyme, respectively. RNA in situ hybridization revealed intestinal stem cells that express Lgr5. ASA administration induced an increase in the mucosal permeability of 2D-hiPSC-SI. ASA-injured 2D-hiPSC-SI showed decreased mRNA expression of multi-lineage small intestinal cell markers as well as intestinal stem cell marker Lgr5. Administration of Irsogladine on the basal side of the 2D-hiPSC-SI resulted in significant increases in Mki67 and Muc2 mRNA expression by 2D-hiPSCs at 48 h compared with the control group. Administration of 400 µg/mL Irsogladine to the ASA-induced small intestinal injury model resulting in significantly decreased mucosal permeability of 2D-hiPSC-SI. In immunofluorescence staining, Irsogladine significantly increased the fluorescence intensity of MUC2 under normal conditions and administration of 400 µg/mL ASA. Conclusions: we established a novel ASA-induced small intestinal injury model using human iPSC-derived small intestine. Irsogladine maintains mucosal permeability and goblet cell differentiation against ASA-induced small intestinal injury." @default.
• W4313471630 created "2023-01-06" @default.
• W4313471630 creator A5006085300 @default.
• W4313471630 creator A5020562439 @default.
• W4313471630 creator A5032900440 @default.
• W4313471630 creator A5037638547 @default.
• W4313471630 creator A5047369080 @default.
• W4313471630 creator A5048470528 @default.
• W4313471630 date "2022-12-31" @default.
• W4313471630 modified "2023-09-30" @default.
• W4313471630 title "Protective Effect of Irsogladine against Aspirin-Induced Mucosal Injury in Human Induced Pluripotent Stem Cell-Derived Small Intestine" @default.
• W4313471630 cites W1562649423 @default.
• W4313471630 cites W1965157206 @default.
• W4313471630 cites W1978910276 @default.
• W4313471630 cites W1985739635 @default.
• W4313471630 cites W1998244718 @default.
• W4313471630 cites W2014385625 @default.
• W4313471630 cites W2016964093 @default.
• W4313471630 cites W2030364983 @default.
• W4313471630 cites W2036990165 @default.
• W4313471630 cites W2048827839 @default.
• W4313471630 cites W2049184320 @default.
• W4313471630 cites W2050532007 @default.
• W4313471630 cites W2098497711 @default.
• W4313471630 cites W2104628930 @default.
• W4313471630 cites W2109963121 @default.
• W4313471630 cites W2111329465 @default.
• W4313471630 cites W2116888841 @default.
• W4313471630 cites W2117459641 @default.
• W4313471630 cites W2121689079 @default.
• W4313471630 cites W2129920713 @default.
• W4313471630 cites W2133848536 @default.
• W4313471630 cites W2141210626 @default.
• W4313471630 cites W2143296478 @default.
• W4313471630 cites W2145725787 @default.
• W4313471630 cites W2146163313 @default.
• W4313471630 cites W2146197194 @default.
• W4313471630 cites W2152652033 @default.
• W4313471630 cites W2153835366 @default.
• W4313471630 cites W2156801000 @default.
• W4313471630 cites W2167595087 @default.
• W4313471630 cites W2261291226 @default.
• W4313471630 cites W2337334490 @default.
• W4313471630 cites W2498968070 @default.
• W4313471630 cites W2583579660 @default.
• W4313471630 cites W2774539331 @default.
• W4313471630 cites W2795590411 @default.
• W4313471630 cites W2901391118 @default.
• W4313471630 cites W2916106050 @default.
• W4313471630 cites W2970582445 @default.
• W4313471630 cites W3011320584 @default.
• W4313471630 cites W3033246556 @default.
• W4313471630 cites W3049637905 @default.
• W4313471630 cites W3085261619 @default.
• W4313471630 cites W3091770177 @default.
• W4313471630 cites W3096525951 @default.
• W4313471630 cites W3131100411 @default.
• W4313471630 cites W3149503624 @default.
• W4313471630 cites W3153683964 @default.
• W4313471630 cites W3155012461 @default.
• W4313471630 doi "https://doi.org/10.3390/medicina59010092" @default.
• W4313471630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36676718" @default.
• W4313471630 hasPublicationYear "2022" @default.
• W4313471630 type Work @default.
• W4313471630 citedByCount "0" @default.
• W4313471630 crossrefType "journal-article" @default.
• W4313471630 hasAuthorship W4313471630A5006085300 @default.
• W4313471630 hasAuthorship W4313471630A5020562439 @default.
• W4313471630 hasAuthorship W4313471630A5032900440 @default.
• W4313471630 hasAuthorship W4313471630A5037638547 @default.
• W4313471630 hasAuthorship W4313471630A5047369080 @default.
• W4313471630 hasAuthorship W4313471630A5048470528 @default.
• W4313471630 hasBestOaLocation W43134716301 @default.
• W4313471630 hasConcept C103395026 @default.
• W4313471630 hasConcept C126322002 @default.
• W4313471630 hasConcept C177779419 @default.
• W4313471630 hasConcept C203014093 @default.
• W4313471630 hasConcept C2777628954 @default.
• W4313471630 hasConcept C2777882243 @default.
• W4313471630 hasConcept C2781071285 @default.
• W4313471630 hasConcept C28328180 @default.
• W4313471630 hasConcept C46699223 @default.
• W4313471630 hasConcept C71315377 @default.
• W4313471630 hasConcept C71924100 @default.
• W4313471630 hasConcept C86803240 @default.
• W4313471630 hasConcept C95444343 @default.
• W4313471630 hasConceptScore W4313471630C103395026 @default.
• W4313471630 hasConceptScore W4313471630C126322002 @default.
• W4313471630 hasConceptScore W4313471630C177779419 @default.
• W4313471630 hasConceptScore W4313471630C203014093 @default.
• W4313471630 hasConceptScore W4313471630C2777628954 @default.
• W4313471630 hasConceptScore W4313471630C2777882243 @default.
• W4313471630 hasConceptScore W4313471630C2781071285 @default.
• W4313471630 hasConceptScore W4313471630C28328180 @default.
• W4313471630 hasConceptScore W4313471630C46699223 @default.
• W4313471630 hasConceptScore W4313471630C71315377 @default.
• W4313471630 hasConceptScore W4313471630C71924100 @default.
• W4313471630 hasConceptScore W4313471630C86803240 @default.

• next